Business Wire

Nocturia: the most common cause of a poor night’s sleep, say experts on World Sleep Day

Jaa

On World Sleep Day, scientists are highlighting the number one reason that people are waking up at night – nocturia (otherwise known as the need to get up and urinate more than once during the night).1,2 It often has one or more contributing factors such as an overproduction of urine, reduced bladder capacity; certain illnesses and medications are also potential contributors.2,6 Although it is most common in older adults, nocturia can affect people of all ages and frequent sleep disturbances significantly impact daily living and can be a sign of more serious health conditions.2,3,4,5

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180315005990/en/

“Nocturia’s disruption to deep sleep results in reduced productivity and alertness that can affect multiple areas of an individual’s life during the day,” said Jens-Peter Nørgaard, Medical Director of Ferring Pharmaceuticals and Professor of Urology at Ghent University, Belgium. “From making it difficult to manage a busy daily schedule to negatively impacting productivity at work, sleep disruption has significant impact far beyond fatigue or night-time inconvenience.”

The effect that sleep disruption can have was measured recently in a study by Nokia Health, which designs smart health devices and apps. In the study sleep patterns were measured using Nokia sleep sensors and compared to self-reported quality of sleep. Of the over 19,000 people surveyed it was shown that frequency of nightly awakenings was the most important factor in getting a good night’s sleep – more than the total duration of sleep or the time people went to bed.7

Lack of sleep from nocturia can lead to impaired daytime functioning, as well as reduced productivity and alertness.3,4,5 These frequent sleep interruptions are important as uninterrupted sleep is needed to sustain physical (including the immune system), mental and emotional health.8

“People often ignore sleep disturbance from nocturia, but this can produce significant disruption to daytime functioning,” said Dr. Andrew Krystal, Professor of Psychiatry and Behavioral Science at University of California, San Francisco. “It is important this is discussed with a healthcare professional, as this disruption is not just harmful in itself but can also be an indicator of more serious health conditions.”

Nocturia can also be a symptom of more serious health problems such as high blood pressure, diabetes and heart disease.2 The impact of sleep disturbances can also lead to greater risk of serious health conditions such as increased risk of diabetes, weakened immune systems and heart disease.9 Similarly, individuals who suffer from chronic sleep disturbances experience reduced cognitive functioning, which can impact productivity, relationships and careers.8

About World Sleep Day
World Sleep Day is an annual event intended to be a celebration of sleep and a call to action on important issues related to sleep. It is organised by the World Sleep Day Committee of the World Sleep Society (founded by World Association of Sleep Medicine and the World Sleep Federation) and will take place on Friday 16th March 2018.10

About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com and @Ferring, or connect with us on Facebook, Instagram and LinkedIn.

Ferring is a proud supporter of World Sleep Day

1 Benefield LE. Facilitating Aging in Place: Safe, Sound, and Secure, An Issue of Nursing Clinics. 2014

2 National Association for Continence. Nocturia web page. Last accessed 2017.

3 Bliwise DL et al. J Clin Sleep Med 2015;11:53–5.

4 Bliwise DL et al. Eur Urol Suppl 2014;13:e591–e591a.

5 Kobelt G, Borgstrom F, Mattiasson A. Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int. 2003;91(3):190–5

6 Park, H.K and Kim, H.G., Current Evaluation and Treatment of Nocturia, Korean J Urol. Aug 2013; 54(8): 492–498. page 492

7 Roitmann, E., O. Bellahsen, and A. Chieh. "Perceived sleep quality of sleep profiles derived from connected sleep detector data." Sleep Medicine 40 (2017): e281-e282.

8 Laureanno, P. Ellsworth, P., Demystifying Nocturia: Identifying the Cause and Tailoring the Treatment. Urol Nurs. 2010;30(5):276-287.

9 Orzel-Gryglewska, J. Consequences of Sleep Deprivation. International Journal of Occupational Medicine and Environmental Health 2010; 23(1): 95-114. doi:10.2478/v10001-010-0004-9.

10 World Sleep Day website. Homepage. [Last accessed February 2017] Available at: www.worldsleepday.org

Contact information

Ferring Pharmaceuticals
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 40 23 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
or
Bhavin Vaid
Head of Corporate Communications
+41 58 301 09 52 (direct)
+41 79 191 06 32 (mobile)
bhavin.vaid@ferring.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Enamine and TBD Biodiscovery Collaborate to Provide GMP-Based Services19.6.2018 11:08Tiedote

Enamine Ltd., a chemical research organization and producer of novel building blocks and screening libraries, and TBD Biodiscovery, a premium GMP manufacturer of fine chemicals including chemical active pharmaceutical ingredients (APIs), today announced they have entered into a collaboration agreement. The partnership aims to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards utilizing Enamine’s know-how and process development expertise. This will help researchers meet the manufacturing feasibility criteria required for drug candidate selection, providing a rapid and cost effective scaled supply of new compounds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180619005582/en/ Enamine’s catalogue of building blocks is the largest in the world and has been widely used by pharmaceutical companies for more than 15 years to develop lead compounds and drug candidat

IDEMIA Selected to Deliver Its Next Generation Fingerprint Matcher Engine as Part of the UK Home Office Biometrics Programme19.6.2018 10:54Tiedote

This award will result in the deployment of the very latest IDEMIA fingerprint matching platform, which will deliver significant productivity improvements by offering increased accuracy fingerprint services to the stakeholders and users of the HOB Programme. In the first phase of the project IDEMIA’s solution will be deployed for use by United Kingdom National Law Enforcement agencies, to be closely followed by Immigration and Border stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180619005576/en/ (Photo: IDEMIA) IDEMIA’s solution is based upon its MBSS Search Platform1 with additional Services. MBSS is a flagship product of IDEMIA, combining very high scalability (over 1 billion identities possible), very high availability – designed for mission-critical systems – and integrating IDEMIA’S world-leading biometric algorithms. The IDEMIA award results from a competitive procurement. Initially a five year contract,

Vincent Fournier Joins Binary Tree as Chief Innovation Officer19.6.2018 10:00Tiedote

Binary Tree has named Vincent Fournier as its first chief innovation officer, reporting to CEO Nick Wilkinson. In this critical executive management role, Vincent will lead a fast-paced, innovative, and collaborative team that helps power digital transformation. His team will develop new products and services to meet the urgent and pervasive needs of customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180619005126/en/ Vincent Fournier, Chief Innovation Officer at Binary Tree. (Photo: Business Wire) “The appointment of Vincent to this important new role is a key part of our strategy to define and accelerate the next phase of growth for Binary Tree and continue to drive our competitive advantage,” said Binary Tree CEO Nick Wilkinson. “We have a clear strategy, focused on transformation, innovation and the evolution of Binary Tree within the broader Microsoft ecosystem.” “I am thrilled to be joining Binary Tree during suc

Janssen Phase 3 Study Programme of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Presented for the First Time in Europe19.6.2018 09:00Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson presented for the first time in Europe data from pivotal Phase 3 clinical studies of the investigational compound esketamine nasal spray in treatment-resistant depression.1,2,3,4 The studies, conducted by Janssen Research & Development, LLC, were presented at the 31st International College of Neuropsychopharmacology (CINP) congress in Vienna, Austria. Data discussed from the Phase 3 programme included results from the maintenance phase of a long-term relapse prevention study in adults with treatment-resistant depression. The data found that continuing treatment with esketamine nasal spray plus an oral antidepressant in patients beyond 16 weeks showed clinically meaningful and statistically significant superiority to treatment with an oral antidepressant plus placebo nasal spray in delaying time to relapse of symptoms of depression. Furthermore, the data indicated that patients in stable remission treated with esketamine nasal sp

Rimini Street Announces $140 Million Refinancing19.6.2018 00:30Tiedote

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has entered into a binding agreement with a syndicate of investors, including a fourth round of equity participation by Rimini Street’s largest shareholder, Adams Street Partners, to refinance its current credit facility with the issuance of $140 million of Series A convertible preferred stock and 2.9 million shares of common stock. Closing is subject to a shareholder vote and certain other customary closing conditions. Holders of a majority of the Company’s common stock have agreed to vote in favor of the transaction, and the Company expects the transaction to close in the third quarter of 2018. The transaction is expected to unlock more than $95 million of cash flow over the next three years as compared to the current credit facility. The transaction extends the expected financing matu

Quanergy to Feature ‘Qortex for Security’ at IFSEC18.6.2018 23:30Tiedote

Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, today announced that it will be demonstrating its LiDAR-based security system at multiple booths during IFSEC International, Europe’s premier security trade show. This year’s conference will take place June 19-21, 2018 in London, UK. Quanergy’s security system, Qortex for Security, is an innovative, LiDAR-based 3D perimeter fencing and intrusion detection system. An integrated hardware and software platform, this intelligent security solution combines Quanergy’s M8 mechanical LiDAR sensor with its proprietary Qortex perception software. The platform is fully integrated into existing VMS (Video Management System) and PSIM (Physical Security Information Management) infrastructure and offers surveillance automation with real-time people detection, tracking and classification. “Qortex for Security is a prime example of the many benefits that LiDAR hardware and sof

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme